Cited by 1,151Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Soria, Jean-Charles, Tan, Daniel S W, Chiari, Rita, Wu, Yi-Long, Paz-Ares, Luis, Wolf, Juergen, Geater, Sarayut L, Orlov, Sergey, Cortinovis, Diego, Yu, Chong-Jen, Hochmair, Maximillian, Cortot, Alexis B, Tsai, Chun-Ming, Moro-Sibilot, Denis, Campelo, Rosario G, McCulloch, Tracey, Sen, Paramita, Dugan, Margaret, Pantano, Serafino, Branle, Fabrice, Massacesi, Cristian, de Castro, Gilberto·2017·The Lancet

DOI 10.1016/s0140-6736(17)30123-x

Open this paper in CoChat — free account

Abstract

Background The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the efficacy and safety of ceritinib versus platinum-based chemotherapy in these patients. Methods This randomised, open-label, phase 3 study in untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC was done in 134 centres across 28 countries. Eligible patients were assigned via interactive response technology to oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin 75 mg/m 2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m 2 ] every 3 weeks for four cycles followed by maintenance pemetrexed); randomisation was stratified by World Health Organization performance status (0 vs 1-2), previous neoadjuvant or adjuvant chemotherapy, and presence of brain metastases as per investigator's assessment at screening. Investigators and patients were not masked to treatment assignment. The primary endpoint was blinded independent review committee assessed progression-free survival, based on all randomly assigned patients (the full analysis set). Efficacy analyses were done based on the full analysis set. All safety analyses were done based on the safety set, which included all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT01828099. Findings Between Aug 19, 2013, and May 11, 2015, 376 patients were randomly assigned to ceriti…

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(17)30123-x

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Self-citation
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M. A., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,873
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Self-citation
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M. A., Solomon, B., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,337
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61497-5 · Cited by 1,111
Self-citation
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 935
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Friboulet, L., Li, N., Katayama, R., Lee, C. C., Gainor, J. F., Crystal, A., Michellys, P., Awad, M. M., Yanagitani, N., Kim, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0846 · Cited by 867
PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Paz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1102 · Cited by 624
Self-citation

Show all 26 references

Sorted by citations

Items 101–200 of 1,000

Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC
Zhang, S. S., Nagasaka, M., Zhu, V. W., & Ou, S. I. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.06.012 · Cited by 114
Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
Tsvetkova, D. D., & Ivanova, S. A. (2022) · Molecules · doi:10.3390/molecules27082466 · Cited by 118
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs
Felip, E., Shaw, A. T., Bearz, A., Camidge, D. R., Solomon, B., Bauman, J. R., Bauer, T. M., Peters, S., Toffalorio, F., Abbattista, A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.012 · Cited by 111
ALK fusions in the pan-cancer setting: another tumor-agnostic target?
Shreenivas, A. V., Jankú, F., Gouda, M. A., Chen, H., George, B., Kato, S., & Kurzrock, R. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00449-x · Cited by 111
Characteristics and Outcome of ROS1-Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice
Park, S., Ahn, B., Lim, S. W., Sun, J., Kim, H. R., Hong, M. H., Lee, S., Ahn, J. S., Park, K., Choi, Y., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.026 · Cited by 109
METExon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations
Socinski, M. A., Pennell, N. A., & Davies, K. D. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00516 · Cited by 104
Conquering lung cancer: current status and prospects for the future
Pirker, R. (2020) · Pulmonology · doi:10.1016/j.pulmoe.2020.02.005 · Cited by 101
Tyrosine Kinase Receptors in Oncology
Esteban-Villarrubia, J., Castillo, J. J. S., Pozas, J., Román, M. S., Orejana, I., Torres-Jiménez, J., Carrato, A., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228529 · Cited by 104
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
Sharma, G. G., Mota, I. A., Mologni, L., Patrucco, E., Gambacorti-Passerini, C. B., & Chiarle, R. (2018) · Cancers · doi:10.3390/cancers10030062 · Cited by 100
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives
Ferrara, M. G., Noia, V. D., D’Argento, E., Vita, E., Damiano, P., Cannella, A., Ribelli, M., Pilotto, S., Milella, M., Tortora, G., et al. (2020) · Cancers · doi:10.3390/cancers12051196 · Cited by 101
Lung Cancer in Republic of China
Luo, Y., Chiu, C., Kuo, C.-H. S., Chou, T., Yeh, Y., Hsu, H., Yen, S.-H., Wu, Y., Yang, J. C., Liao, B.-C., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.155 · Cited by 98
Self-citation
Breakthrough in targeted therapy for non-small cell lung cancer
Zhencong, Y., Huang, Y., Ke, J., Zhu, X. M., Leng, S., & Luo, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111079 · Cited by 100
Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors
Sgambato, A., Casaluce, F., Maione, P., & Gridelli, C. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1412260 · Cited by 93
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma
Rybarczyk-Kasiuchnicz, A., Ramlau, R., & Stencel, K. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020593 · Cited by 94
Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces
Huang, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113448 · Cited by 89
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer
Yang, J. C., Ou, S. I., Petris, L. D., Gadgeel, S. M., Gandhi, L., Kim, D., Barlési, F., Govindan, R., Dingemans, A. C., Crinò, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.06.070 · Cited by 85
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
Lin, J. J., Zhu, V. W., Schoenfeld, A. J., Yeap, B. Y., Saxena, A., Ferris, L. A., Dagogo‐Jack, I., Farago, A. F., Taber, A. M., Traynor, A. M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.005 · Cited by 84
ALK Inhibitors in the Treatment of ALK Positive NSCLC
Khan, M. B., Lin, J., Liao, G., Tian, Y., Liang, Y., Li, R., Liu, M., & Yuan, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00557 · Cited by 84
Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
Remón, J., Ahn, M., Girard, N., Johnson, M. L., Kim, D., Lopes, G. D. L., Jr., Pillai, R. N., Solomon, B., Villacampa, G. J., & Zhou, Q. H. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.022 · Cited by 84
Brain metastases in oncogene-driven non-small cell lung cancer
Nishino, M., Soejima, K., & Mitsudomi, T. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.05.15 · Cited by 84
Enabling Precision Oncology Through Precision Diagnostics
Brown, N. A., & Elenitoba‐Johnson, K. S. J. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012735 · Cited by 84
Molecular therapeutic targets in non-small cell lung cancer
Sankar, K. N., Gadgeel, S. M., & Qin, A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1787156 · Cited by 85
Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)
Xie, S., Sun, Y., Liu, Y., Li, X., Li, X., Zhong, W., Zhan, F., Zhu, J., Yao, H., Yang, D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00270 · Cited by 81
Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
Seegobin, K., Majeed, U., Wiest, N. E., Manochakian, R., Lou, Y., & Zhao, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.750657 · Cited by 83
Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks
Palechor-Ceron, N., Krawczyk, E., Dakic, A., Simić, V., Yuan, H., Blancato, J. K., Wang, W., Hubbard, F. A., Zheng, Y., Dan, H., et al. (2019) · Cells · doi:10.3390/cells8111327 · Cited by 80
ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis
Elliott, J., Bai, Z., Hsieh, S., Kelly, S., Chen, L., Skidmore, B., Yousef, S., Zheng, C., Stewart, D. J., & Wells, G. A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229179 · Cited by 81
Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer
Rivera‐Concepción, J., Uprety, D., & Adjei, A. A. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2022.078 · Cited by 84
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer
Shiba‐Ishii, A., Johnson, T. W., Dagogo‐Jack, I., Mino-Kenudson, M. A., Johnson, T. R., Wei, P. Y., Weinrich, S. L., McTigue, M. A., Walcott, M., Nguyen-Phuong, L., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00399-6 · Cited by 80
Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment
Remón, J., & Besse, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00088 · Cited by 80
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors
Lin, J. J., Schoenfeld, A. J., Zhu, V. W., Yeap, B. Y., Chin, E. N., Rooney, M. M., Plodkowski, A. J., Digumarthy, S. R., Dagogo‐Jack, I., Gainor, J. F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.014 · Cited by 78
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study
Felip, E., de Braud, F., Maur, M., Loong, H. H.-F., Shaw, A. T., Vansteenkiste, J., John, T., Liu, G., Lolkema, M. P., Selvaggi, G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.006 · Cited by 76
Self-citation
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer
Remón, J., Pignataro, D., Novello, S., & Passiglia, F. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102178 · Cited by 77
Adenocarcinoma of the Lung in Childhood and Adolescence: A Systematic Review
Balzer, B. W. R., Loo, C. K. C., Lewis, C. R., Trahair, T. N., & Anazodo, A. C. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2020 · Cited by 75
Targeting anaplastic lymphoma kinase in neuroblastoma
Umapathy, G., Mendoza-García, P., Hallberg, B., & Palmer, R. H. (2019) · Apmis · doi:10.1111/apm.12940 · Cited by 74
The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
Gristina, V., Mantia, M. L., Iacono, F., Galvano, A., Russo, A. D., & Bazan, V. (2020) · Pharmaceuticals · doi:10.3390/ph13120474 · Cited by 73
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study
Cho, B. C., Obermannova, R. L., Bearz, A., McKeage, M. J., Kim, D.-W., Batra, U., Borra, G., Orlov, S., Kim, S.-W., Geater, S. L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.002 · Cited by 72
Self-citation
Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
Garinet, S., Laurent‐Puig, P., Blons, H., & Oudart, J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7060144 · Cited by 71
Targeting ALK Rearrangements in NSCLC: Current State of the Art
Peng, L., Zhu, L., Sun, Y., Stebbing, J., Selvaggi, G., Zhang, Y., & Yu, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.863461 · Cited by 71
Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications
Imperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 74
Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review
Ninatti, G., Kirienko, M., Neri, E., Sollini, M., & Chiti, A. (2020) · Diagnostics · doi:10.3390/diagnostics10060359 · Cited by 72
Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial
Nishio, M., Yoshida, T., Kumagai, T., Hida, T., Toyozawa, R., Shimokawaji, T., Goto, K., Nakagawa, K., Ohe, Y., Seto, T., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.004 · Cited by 70
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC
Zhu, V. W., Lin, Y.-T., Kim, D., Loong, H. H.-F., Nagasaka, M., To, H., Ang, Y. L. E., Ock, C.-Y., Tchekmedyian, N., Ou, S. I., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.04.019 · Cited by 70
Omics-based deep learning approaches for lung cancer decision-making and therapeutics development
Tran, T.-O., Vo, T. H., & Le, N. Q. K. (2023) · Briefings in Functional Genomics · doi:10.1093/bfgp/elad031 · Cited by 68
A systematic review of targeted agents for non-small cell lung cancer
Vestergaard, H. H., Christensen, M. R., & Lassen, U. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1404634 · Cited by 66
Drug resistance in anaplastic lymphoma kinase‐rearranged lung cancer
Katayama, R. (2018) · Cancer Science · doi:10.1111/cas.13504 · Cited by 66
Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer
Jahanzeb, M., Lin, H. M., Pan, X., Yin, Y., Baumann, P., & Langer, C. J. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.08.003 · Cited by 65
Lung Toxicity in Non–Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature
Pellegrino, B., Facchinetti, F., Bordi, P., Silva, M., Gnetti, L., & Tiseo, M. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.10.008 · Cited by 65
Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities
Yoda, S., Dagogo‐Jack, I., & Hata, A. N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.007 · Cited by 68
Risk of thromboembolism in patients with ALK‐ and EGFR‐mutant lung cancer: A cohort study
Roopkumar, J., Poudel, S. K., Gervaso, L., Reddy, C. A., Velcheti, V., Pennell, N. A., McCrae, K. R., & Khorana, A. A. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15215 · Cited by 65
Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)
Omar, N. E., Soliman, A. I. F., Eshra, M. R., Saeed, T., Hamad, A., & Abou‐Ali, A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100315 · Cited by 63
Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer
Pan, K., Concannon, K., Li, J., Zhang, J., Heymach, J. V., & Le, X. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00808-4 · Cited by 65
Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead
Ulahannan, D., Khalifa, J., Finn, C. F., & Lee, S. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx481 · Cited by 63
Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer
Chuang, C., Chen, H., Chang, H.-M., Tsai, Y.-C., Wu, K., Chen, I.-H., Chen, K.-C., Lee, J., Chang, Y.-C., Chen, C.-L., et al. (2021) · Cancers · doi:10.3390/cancers13081966 · Cited by 63
Lung Cancer: Targeted Therapy in 2025
Bouchard, N., & Daaboul, N. (2025) · Current Oncology · doi:10.3390/curroncol32030146 · Cited by 64
The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
Hou, H., Sun, D., Liu, K., Jiang, M., Liu, D., Zhu, J., Zhou, N., Cong, J., & Zhang, X. (2019) · Cancer Management and Research · doi:10.2147/cmar.s190098 · Cited by 63
Inhalable pH-responsive DNA tetrahedron nanoplatform for boosting anti-tumor immune responses against metastatic lung cancer
Qin, F., Li, Z., Yin, J., Xie, M., Cui, M.-R., Fan, C., Wang, L., & Chao, J. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122283 · Cited by 61
Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners
Reed, M. L., Rosales, A.-L. S., Chioda, M. D., Parker, L., Devgan, G., & Kettle, J. K. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01365-3 · Cited by 60
Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review
Li, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4444 · Cited by 68
A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer
Pacheco, J. M., Camidge, D. R., Doebele, R. C., & Schenk, E. L. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00195 · Cited by 60
Imaging of Precision Therapy for Lung Cancer: Current State of the Art
Park, H., Sholl, L. M., Hatabu, H., Awad, M. M., & Nishino, M. (2019) · Radiology · doi:10.1148/radiol.2019190173 · Cited by 61
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions
Choudhury, N. J., Schoenfeld, A. J., Flynn, J. R., Falcon, C. J., Rizvi, H. A., Rudin, C. M., Kris, M. G., Arcila, M. E., Heller, G., Yu, H. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4650 · Cited by 60
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
Wang, Z., Xing, Y., Li, B., Li, X., Liu, B., & Wang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00107-x · Cited by 62
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
Cameron, L. B., Hitchen, N., Chandran, E. B. A., Morris, T., Manser, R., Solomon, B., & Jordan, V. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013453.pub2 · Cited by 58
The Landscape of Actionable Gene Fusions in Colorectal Cancer
Pagani, F., Randon, G., Guarini, V., Raimondi, A., Prisciandaro, M., Lobefaro, R., Bartolomeo, M. D., Sozzi, G., de Braud, F., Gasparini, P., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215319 · Cited by 58
Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
Dolly, S. O., Collins, D. C., Sundar, R., Popat, S., & Yap, T. A. (2017) · Drugs · doi:10.1007/s40265-017-0732-2 · Cited by 59
Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND ‐9
Hida, T., Seto, T., Horinouchi, H., Maemondo, M., Takeda, M., Hotta, K., Hirai, F., Kim, Y. H., Matsumoto, S., Ito, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13721 · Cited by 57
Brain Metastases in Non-Small-Cell Lung Cancer: Are Tyrosine Kinase Inhibitors and Checkpoint Inhibitors Now Viable Options?
Abdallah, S. M.-B., & Wong, A. N. M. (2018) · Current Oncology · doi:10.3747/co.25.3733 · Cited by 57
Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions
Couñago, F., Luna, J., Guerrero, L. L., Barrón, B. V., Guillen-Sacoto, M. C., González-Merino, T., Taboada, B., Díaz, V. D., Rubio‐Viqueira, B., Díaz-Gavela, A. A., et al. (2019) · World Journal of Clinical Oncology · doi:10.5306/wjco.v10.i10.318 · Cited by 57
Update on the Management of Brain Metastasis
Singh, K., Saxena, S., Khosla, A. A., McDermott, M. W., Kotecha, R. R., & Ahluwalia, M. S. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01312-w · Cited by 56
New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives
de Mello, R. A., Neves, N. M., Tadokoro, H., Amaral, G. A., Castelo‐Branco, P., & Zia, V. A. D. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113543 · Cited by 59
Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion
Chu, Q. S.-C. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919895756 · Cited by 56
Scientific Advances in Thoracic Oncology 2016
Soo, R. A., Stone, E. C. A., Cummings, K. M., Jett, J. R., Field, J. K., Groen, H. J. M., Mulshine, J. L., Yatabe, Y., Bubendorf, L., Đačić, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.019 · Cited by 55
Self-citation
Alectinib: A Review in Advanced, ALK-Positive NSCLC
Paik, J., & Dhillon, S. (2018) · Drugs · doi:10.1007/s40265-018-0952-0 · Cited by 56
Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms
Griesinger, F., Roeper, J., Pöttgen, C., Willborn, K., & Eberhardt, W. (2018) · Oncotarget · doi:10.18632/oncotarget.26073 · Cited by 55
New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations
Attili, I., Corvaja, C., Spitaleri, G., Signore, E. D., Aliaga, P. T., Passaro, A., & de Marinis, F. (2023) · Cancers · doi:10.3390/cancers15205079 · Cited by 56
Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
Wei, J., van der Wekken, A. J., Saber, A., Terpstra, M. M., Schuuring, E. M. D., Timens, W., Hiltermann, T. J. N., Groen, H. J. M., den Berg, A. V., & Kok, K. (2018) · Cancers · doi:10.3390/cancers10010010 · Cited by 54
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
Guha, A., Armanious, M. A., & Fradley, M. G. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.001 · Cited by 54
Facile and highly sensitive photoelectrochemical biosensing platform based on hierarchical architectured polydopamine/tungsten oxide nanocomposite film
Yu, Y., Huang, Z., Zhou, Y., Zhang, L., Liu, A., Chen, W., Lin, J., & Peng, H. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2018.10.026 · Cited by 53
The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis
Suh, C. H., Kim, K. W., Pyo, J., Hatabu, H., & Nishino, M. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.015 · Cited by 55
Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients
Schluckebier, L. F., Caetano, R., Garay, O. U., Montenegro, G., Custódio, M. G., Aran, V., & Ferreira, C. G. (2020) · BMC Cancer · doi:10.1186/s12885-020-07240-2 · Cited by 54
Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review
Desai, A. P., & Lovly, C. M. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-708 · Cited by 55
Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario
Addeo, A., Tabbò, F., Robinson, T., Buffoni, L., & Novello, S. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.12.015 · Cited by 52
Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies
Petrelli, F., Lazzari, C., Ardito, R., Borgonovo, K., Bulotta, A., Conti, B., Cabiddu, M., Capitanio, J. F., Brighenti, M., Ghilardi, M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201425 · Cited by 52
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK -Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
Chow, L. Q. M., Barlési, F., Bertino, E. M., van den Bent, M. J., Wakelee, H. A., Wen, P. Y., Chiu, C.-H., Orlov, S., Chiari, R., Majem, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1838 · Cited by 53
Self-citation
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence
Ricciuti, B., Brambilla, M., Metro, G., Baglivo, S., Matocci, R., Pirro, M., & Chiari, R. (2017) · Medical Oncology · doi:10.1007/s12032-017-0967-5 · Cited by 51
Self-citation
The multifaceted roles of FOXM1 in pulmonary disease
Li, Y., Wu, F., Tan, Q., Guo, M., Ma, P., Wang, X., Zhang, S., Xu, J., Luo, P., & Jin, Y. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0347-1 · Cited by 53
Therapeutic Sequencing in ALK+ NSCLC
Elsayed, M., & Christopoulos, P. (2021) · Pharmaceuticals · doi:10.3390/ph14020080 · Cited by 52
Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)
Iwama, E., Goto, Y., Murakami, H., Harada, T., Tsumura, S., Sakashita, H., Mori, Y., Nakagaki, N., Fujita, Y., Seike, M., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.02.012 · Cited by 52
ALK Inhibitors, Resistance Development, Clinical Trials
Rothenstein, J. M., & Chooback, N. (2018) · Current Oncology · doi:10.3747/co.25.3760 · Cited by 51
Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases
Lin, J. J., Jiang, G. Y., Joshipura, N. D., Ackil, J., Digumarthy, S. R., Rincon, S., Yeap, B. Y., Gainor, J. F., & Shaw, A. T. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.002 · Cited by 52
ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer
Rosas, G., Ruiz, R., Araujo, J. M., Pinto, J. A., & Mas, L. A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.02.006 · Cited by 53
Multidisciplinary patient-centered management of brain metastases and future directions
Palmer, J. D., Trifiletti, D. M., Gondi, V., Chan, M. D., Minniti, G. C., Rusthoven, C. G., Schild, S. E., Mishra, M. V., Bovi, J. A., Williams, N. O., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa034 · Cited by 52
Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?
Ou, S. I., Nagasaka, M., Brazel, D., Hou, Y., & Zhu, V. W. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101191 · Cited by 52
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK + Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
Dziadziuszko, R., Peters, S., Mok, T., Camidge, D. R., Gadgeel, S. M., Ou, S.-H. I., Konopa, K., Noé, J., Nowicka, M., Bordogna, W., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2840 · Cited by 50
The efficacy and safety of ALK inhibitors in the treatment of ALK ‐positive non‐small cell lung cancer: A network meta‐analysis
Fan, J., Fong, T. H., Xia, Z., Zhang, J., & Luo, P. (2018) · Cancer Medicine · doi:10.1002/cam4.1768 · Cited by 50
Progress in the Management of Advanced Thoracic Malignancies in 2017
Ferrara, R., Mezquita, L., & Besse, B. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.01.002 · Cited by 50
Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
Remón, J., Hendriks, L. E. L., Cabrera, C., Reguart, N., & Besse, B. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.006 · Cited by 49
Precision oncology: separating the wheat from the chaff
Remón, J., & Dienstmann, R. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000446 · Cited by 49
Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review
Kassem, L. M. H., Shohdy, K. S., Lasheen, S., Abdel-Rahman, O. M., Ali, A., & Abdelmalek, R. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.11.004 · Cited by 49
Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases
Tomasini, P., Egea, J., Souquet-Bressand, M., Greillier, L., & Barlési, F. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619831906 · Cited by 54

Authors: Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., Hochmair, M., Cortot, A. B., Tsai, C.-M., Moro-Sibilot, D., Campelo, R. G., McCulloch, T., Sen, P., Dugan, M., Pantano, S., Branle, F., Massacesi, C., & de Castro, G.
Affiliations: Université Paris-Sud (FR)
National Cancer Centre Singapore (SG)
Azienda Ospedaliera di Perugia (IT)
Guangdong General Hospital (CN)
Universidad Complutense de Madrid (ES)
University Hospital Cologne (DE)
Songklanagarind Hospital (TH)
Azienda Ospedaliera San Gerardo (IT)
National Taiwan University Hospital (TW)
Otto Wagner Hospital (AT)
Centre Hospitalier Universitaire de Lille (FR)
Taipei Veterans General Hospital (TW)
Universidade da Coruña (ES)
Novartis (Switzerland) (CH)
Corresponding author: Soria, Jean-Charles
ORCID: Soria, Jean-Charles
Tan, Daniel S W
Chiari, Rita
Wu, Yi-Long
Paz-Ares, Luis
Geater, Sarayut L
Cortinovis, Diego
Yu, Chong-Jen
Hochmair, Maximillian
Cortot, Alexis B
Tsai, Chun-Ming
Campelo, Rosario G
Branle, Fabrice
Venue: The Lancet
Publisher: Elsevier BV
Published: 2017-03
Volume: 389
Issue: 10072
Pages: 917-929
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(17)30123-x
OpenAlex: W2581996620
Cited by: 1,151
References: 26
Citations by year: 2026: 38 · 2025: 73 · 2024: 98 · 2023: 123 · 2022: 142 · 2021: 128 · 2020: 139 · 2019: 146 · 2018: 168 · 2017: 94
FWCI: 123.94
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
BOA (University of Milano-Bicocca) (submittedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: ceritinib, anaplastic lymphoma kinase, ALK-positive non-small cell lung cancer, first-line therapy, platinum-based chemotherapy, pemetrexed, progression-free survival, targeted therapy, adverse events, diarrhea, elevated liver enzymes, brain metastases, treatment safety and efficacy comparison, WHO performance status
MeSH terms: Pemetrexed, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Lung Neoplasms, Male, Middle Aged, Pyrimidines, Sulfones, Carboplatin, Treatment Outcome, Disease-Free Survival, Kaplan-Meier Estimate, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks